Mitsubishi Electric Group Launches New Corporate Philosophy

Promoting transformation into an “Innovative Company”

TOKYO--(BUSINESS WIRE)-- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has launched Mitsubishi Electric group’s new corporate philosophy, named Our Philosophy, to update the corporate spirit long upheld by the company and its global group.

Mitsubishi Electric aims to transform into an “Innovative Company” that generates value through bold thinking and a willingness to embrace risk while operating diverse global businesses to drive growth and address social and environmental challenges.

To achieve further growth amid rapidly changing social trends and business conditions, the company recognizes the need to make faster, more agile decisions than ever before. Accordingly, the new corporate philosophy provides employees with a touchstone when facing uncertainty in decision-making, as well as a guiding framework when taking new initiatives. Our Philosophy comprises three basic elements: “Purpose,” “Guiding Principle,” and “Core Values.”

With Our Philosophy as its foundation, Mitsubishi Electric is committed to creating new possibilities for a better tomorrow through bold vision and boundless innovation.

For the full text, please visit: www.MitsubishiElectric.com/news/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260331204651/en/

Customer Inquiries
Mitsubishi Electric Corporation
www.MitsubishiElectric.com/ssl/contact/company/form.html

Media Inquiries
Takeyoshi Komatsu
Public Relations Division
Mitsubishi Electric Corporation
Tel: +81-3-3218-2332
[email protected]
www.MitsubishiElectric.com/en/pr/

Source: Mitsubishi Electric Corporation

You May Also Be Interested In

• Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
• ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement
• Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States